Literature DB >> 23669263

Quality control of the surveillance programme of ICU-acquired infection (ENVIN-HELICS registry) in Spain.

M J López-Pueyo1, P Olaechea-Astigarraga, M Palomar-Martínez, J Insausti-Ordeñana, F Alvarez-Lerma.   

Abstract

BACKGROUND: Data validation is an essential aspect for the accuracy of a nosocomial infection surveillance registry. AIM: To report the results of the first quality control programme in the national surveillance programme of intensive care unit (ICU)-acquired infection in Spain (ENVIN-HELICS registry).
METHOD: During 2008, of 13,824 records included in the database, 1500 (10.8%) registries from 20 ICUs were reviewed. These ICUs were selected at random and stratified according to the number of cases included in the registry. The proportion of infected patients, which was 9.6% [95% confidence interval (CI) 8.09-11.16], was maintained during the selection of cases for review. Two physicians were trained for the purpose of the study and undertook the review.
RESULTS: Overall sensitivity, specificity and positive and negative predictive values of the ENVIN-HELICS registry for the identification of patients with any device-related infection acquired during their ICU stay were 86.0% (95% CI 80.0-92.0), 98.7% (95% CI 82.19-93.6), 87.9% (95% CI 82.19-93.6) and 98.5% (95% CI 97.8-99.2), respectively, with a kappa index of 0.85 (95% CI 0.79-0.92). Secondary bloodstream infection had the lowest sensitivity (59.3%), and intubation-associated pneumonia had the highest sensitivity (86.3%).
CONCLUSION: There was good correlation between data reported by the registrars and data validated by auditors, confirming the reliability of the ENVIN-HELICS registry.
Copyright © 2013 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23669263     DOI: 10.1016/j.jhin.2013.02.018

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  6 in total

1.  A comparison of diagnostic algorithms and clinical parameters to diagnose ventilator-associated pneumonia: a prospective observational study.

Authors:  Farshid Rahimibashar; Andrew C Miller; Mojtaba H Yaghoobi; Amir Vahedian-Azimi
Journal:  BMC Pulm Med       Date:  2021-05-13       Impact factor: 3.317

2.  Epidemiology, associated factors and outcomes of ICU-acquired infections caused by Gram-negative bacteria in critically ill patients: an observational, retrospective study.

Authors:  Cosimo Chelazzi; Eleonora Pettini; Gianluca Villa; A Raffaele De Gaudio
Journal:  BMC Anesthesiol       Date:  2015-09-21       Impact factor: 2.217

3.  Multilevel competing risk models to evaluate the risk of nosocomial infection.

Authors:  Martin Wolkewitz; Ben S Cooper; Mercedes Palomar-Martinez; Francisco Alvarez-Lerma; Pedro Olaechea-Astigarraga; Adrian G Barnett; Stephan Harbarth; Martin Schumacher
Journal:  Crit Care       Date:  2014-04-08       Impact factor: 9.097

4.  Study of risk factors for healthcare-associated infections in acute cardiac patients using categorical principal component analysis (CATPCA).

Authors:  Emilio Renes Carreño; Almudena Escribá Bárcena; Mercedes Catalán González; Francisco Álvarez Lerma; Mercedes Palomar Martínez; Xavier Nuvials Casals; Felisa Jaén Herreros; Juan Carlos Montejo González
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  Challenges of and corrective recommendations for healthcare-associated infection's case findings and reporting from local to national level in Iran: a qualitative study.

Authors:  Nahid Dehghan-Nayeri; Arash Seifi; Leili Rostamnia; Shokoh Varaei; Vahid Ghanbari; Ali Akbari Sari; Hamid Haghani
Journal:  BMC Nurs       Date:  2022-07-19

6.  Multiple time scales in modeling the incidence of infections acquired in intensive care units.

Authors:  Martin Wolkewitz; Ben S Cooper; Mercedes Palomar-Martinez; Francisco Alvarez-Lerma; Pedro Olaechea-Astigarraga; Adrian G Barnett; Martin Schumacher
Journal:  BMC Med Res Methodol       Date:  2016-09-01       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.